RxDoctor Payments Data

Mark Yazer

Pittsburgh, PANPI 1609842913

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $2,169,765 of the $2,185,783 with a category attached, or 99.3%. Vitalant accounts for 89.2% of it on its own, with 4 other manufacturers making up the rest.

$2,185,783in general payments, 2019–2025

Across 73 payments — averaging $29,942 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vitalant$1.9M
  • Institute For Transfusion Medicine$209K
  • Grifols, S.A.$18K
  • Grifols Diagnostic Solutions, Inc.$5K
  • Terumo BCT, Inc.$4K
$1,920in research payments, 2019–2025

Across 2 payments — averaging $960.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Octapharma USA, Inc.$2K

What the payments were for

  • Consulting fees$9,8000%
  • Speaking & faculty fees$2,169,76599%
  • Travel & lodging$6,1550%
  • Food & beverage$630%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →